scholarly journals Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma

2001 ◽  
Vol 7 (10) ◽  
pp. 561-567 ◽  
Author(s):  
Jesüs G. Berdeja ◽  
Richard J. Jones ◽  
Marianna L. Zahurak ◽  
Steven Piantadosi ◽  
Ross A. Abrams ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Mantle Cell Lymphoma ◽  
Marrow Transplantation ◽  
Cell Lymphoma ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Low Grade ◽  
Allogeneic Bone ◽  
Mantle Cell

Allogeneic bone marrow transplantation for refractory mantle cell lymphoma

2000 ◽  
Vol 79 (10) ◽  
pp. 578-580 ◽  
Author(s):  
N. Kröger ◽  
M. Hoffknecht ◽  
W. Krüger ◽  
W. Zeller ◽  
H. Renges ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Mantle Cell Lymphoma ◽  
Marrow Transplantation ◽  
Cell Lymphoma ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Mantle Cell

Hepatosplenic γδ T-cell lymphoma after allogeneic bone marrow transplantation

2015 ◽  
Vol 94 (6) ◽  
pp. 1077-1078 ◽  
Author(s):  
Marie-Christiane Vekemans ◽  
Lucienne Michaux ◽  
Pascale Saussoy ◽  
Eric Van Den Neste ◽  
Ivan Théate ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
T Cell ◽  
Marrow Transplantation ◽  
Cell Lymphoma ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
T Cell Lymphoma ◽  
Allogeneic Bone ◽  
Γδ T Cell

Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.

1995 ◽  
Vol 13 (5) ◽  
pp. 1096-1102 ◽  
Author(s):  
K W van Besien ◽  
I F Khouri ◽  
S A Giralt ◽  
P McCarthy ◽  
R Mehra ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Low Grade ◽  
Allogeneic Bone ◽  
Actuarial Survival ◽  
Prognostic Features ◽  
Allogeneic Bmt

PURPOSE To evaluate the role of allogeneic bone marrow transplantation (BMT) in recurrent low-grade lymphoma. PATIENTS AND METHODS Between 1989 and 1994, 10 patients with chemotherapy-refractory and recurrent low-grade lymphoma were treated with myeloablative therapy and allogeneic BMT. All patients had poor prognostic features and had been extensively pretreated. RESULTS Eight patients achieved a complete remission and none have relapsed at a median follow-up time of 816 days (range, 346 to 1,865). Two patients died of early complications. The actuarial survival and failure-free survival rates are both 80% +/- 12.6%. For surviving patients, the duration of the current remission exceeds that of any previous remission achieved. CONCLUSION These results compare favorably with those for autologous BMT. Allogeneic BMT offers considerable promise for the treatment of patients with poor-prognosis low-grade lymphoma. Its role should be further defined in prospective studies.

Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors.

1991 ◽  
Vol 9 (10) ◽  
pp. 1848-1859 ◽  
Author(s):  
J H Lundberg ◽  
R M Hansen ◽  
C R Chitambar ◽  
C A Lawton ◽  
M Gottlieb ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
T Cell ◽  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Low Grade ◽  
Allogeneic Bone ◽  
Free Survival ◽  
Refractory Lymphoma

Twenty-two patients, ages 16.6 to 43.9 years (median age, 30 years), with relapsed or refractory lymphoma were treated by allogeneic bone marrow transplantation after high-dose chemotherapy with or without total body irradiation (TBI). Seven patients had Hodgkin's disease, four had low-grade histology non-Hodgkin's lymphoma (NHL), seven had intermediate-grade NHL, and four had high-grade NHL. Of the 22 patients, 17 received T-cell (CD-3)-depleted marrow after intensive pretransplant chemoradiotherapy, and five received T-cell-replete grafts after chemotherapy-based preparative regimens. Five patients were transplanted from donors other than genotypically HLA-identical siblings: four from partially HLA-matched relatives, and one from a phenotypically HLA-identical unrelated donor. Acute graft-versus-host disease (GVHD) was less than or equal to grade II in all patients, and chronic GVHD was limited or absent in all but one patient. Of the 21 assessable patients, 17 (80.9%) achieved complete remissions. Death due to transplant-associated complications occurred in five patients, and five patients have relapsed. Thirteen patients are alive, and 12 are continuously relapse-free at a median follow-up of longer than 28 months (range, greater than 10 to greater than 58 months) from transplant. The cumulative probability of treatment failure from relapse or progression of lymphoma was 29% (95% confidence interval [CI], 12% to 51%), while the actuarial lymphoma-free (ie, event-free) survival plateau is 54.6% (95% CI, 34% to 76%). For young patients with advanced malignant lymphoma, allogeneic bone marrow transplantation appears superior to salvage chemotherapy for achievement of long-term, lymphoma-free survival and may be preferable to autologous bone marrow transplantation for selected patients.

Sign in / Sign up

Export Citation Format

Share Document